Regulus reports Q2 EPS (17c), consensus (15c)

As of June 30, 2024, the Company had $95.9M in cash, cash equivalents, and investments. The Company expects its cash runway to extend into H1 2026. “We were very pleased with the data we shared in the second quarter from our ongoing Phase 1b MAD study. Data from cohort three showed continued improvement on both polycystin and height adjusted total kidney volume after just three months of treatment, consistent with what was observed in cohort 2 but with greater mechanistic activity in polycystin changes and more patients showing reductions in kidney volume,” said Jay Hagan, CEO. “This growing data set leaves us excited about the potential of RGLS8429 as a treatment for those living with ADPKD, a disease with high unmet need and limited treatment options. We remain on track to meet with FDA near the end of this year.”